ArticleOncotarget2016
Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- A systematic review of progress toward unlocking the power of epigenetics in breast cancer: latest updates and perspectives.Frontiers in pharmacology · 2025Pooled it
- Diagnostic value of RASSF1A methylation for breast cancer: a meta-analysis.Bioscience reports · 2019Pooled it
- Pooled it
- Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.Medicine · 2018Pooled it
- The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.BMC cancer · 2017Pooled it
- CDKN2A methylation in esophageal cancer: a meta-analysis.Oncotarget · 2017Pooled it
- High levels of circulating folate concentrations are associated with DNA methylation of tumor suppressor and repair genesClinical epigenetics · 2017Trial
- Epigenome-Wide DNA Methylation Profiling of Matched Primary Breast Cancers and Brain Metastases Reveals Epigenetic Markers linked to Metastatic Progression: A Preliminary Study.International journal of medical sciences · 2026Article
- Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer.NPJ breast cancer · 2025Article
- DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?Epigenomics · 2025Review
- Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer.Expert reviews in molecular medicine · 2025Review
- An Approach for Differential Diagnosis of Breast Tumors by ctDNA Methylation Sequencing.Cancer medicine · 2025Article
- Association between single nucleotide polymorphisms of DNA repair genes (BRCA1, BRCA2, and PALB2) and breast cancer incidence in a subset of Iranian population.Hereditary cancer in clinical practice · 2025Article
- Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment.Discover oncology · 2025Review
- Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.MedComm · 2024Review
- Return on investment in science: twenty years of European Commission funded research in Alzheimer's dementia, breast cancer and prostate cancer.Cost effectiveness and resource allocation : C/E · 2024Article
- The Association of Methylation Status and Expression Level ofInternational journal of hematology-oncology and stem cell research · 2023Article
- SOCS1 methylation level is associated with prognosis in patients with acute-on-chronic hepatitis B liver failure.Clinical epigenetics · 2023Article
- Review
- Multimodal analysis of genome-wide methylation, copy number aberrations, and end motif signatures enhances detection of early-stage breast cancer.Frontiers in oncology · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detection of breast cancer at an early stage is the key for successful treatment and improvement of outcome. However the limitations of mammography are well recognized, especially for those women with premenopausal breast cancer. Novel approaches to breast cancer screening are necessary, especially in the developing world where mammography is not feasible. In this study, we examined the promoter methylation of six genes (SFN, P16, hMLH1, HOXD13, PCDHGB7 and RASSF1a) in circulating free DNA (cfDNA) extracted from serum. We used a high-throughput DNA methylation assay (MethyLight) to examine serum from 749 cases including breast cancer patients, patients with benign breast diseases and healthy women. The six-gene methylation panel test achieved 79.6% and 82.4% sensitivity with a specificity of 72.4% and 78.1% in diagnosis of breast cancer when compared with healthy and benign disease controls, respectively. Moreover, the methylation panel positive group showed significant differences in the following independent variables: (a) involvement of family history of tumors; (b) a low proliferative index, ki-67; (c) high ratios in luminal subtypes. Additionally the panel also complemented some breast cancer cases which were neglected by mammography or ultrasound. These data suggest that epigenetic markers in serum have potential for diagnosis of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.